Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer

Cancer Immunology Immunotherapy(2025)10.1007/s00262-025-04096-ySource: DataRank Database

Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer is a research paper published in Cancer Immunology Immunotherapy (2025). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.88)OA: goldTopics (76)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Anna Bianchi ORCID,Haleh Amirian ORCID,Iago De Castro Silva ORCID,Christine I. Rafie ORCID,Bapurao Surnar ORCID

Live enrichment

PubMed:40549154 PMC:PMC12185796 OpenAlex:https://openalex.org/W4411566301

Pancreatic Cancer Action Network

Grant: 22-20-DATT

U.S. Department of Defense

Grant: HT9425310699

NCI NIH HHS

Grant: P30 CA240139

NIAID NIH HHS

Grant: T32 AI162624

National Institutes of Health

Grant: 3P30CA240139-02S3

The Sylvester Cancer Center Support Grant

FWCI

1.88

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://link.springer.com/content/pdf/10.1007/s00262-025-04096-y.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-025-04096-y.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-025-04096-y/fulltext.html

journalhttps://doi.org/10.1007/s00262-025-04096-y

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40549154

Fields of Study

Pancreatic and Hepatic Oncology ResearchPhagocytosis and Immune RegulationImmune cells in cancer03 medical and health sciences0302 clinical medicineAnimalsMyeloid-Derived Suppressor CellsMiceHumansPancreatic NeoplasmsPyrimidinesCarcinoma, Pancreatic DuctalSignal TransductionPyrazolesNanoparticlesReceptors, Interleukin-8BCell Line, TumorMice, Inbred C57BLFemaleNitrilesImmune Tolerance

MeSH Terms

Myeloid-Derived Suppressor CellsAnimalsFemaleHumansImmune ToleranceMice, Inbred C57BLNitrilesPancreatic NeoplasmsPyrazolesPyrimidinesSignal TransductionCarcinoma, Pancreatic DuctalReceptors, Interleukin-8BCell Line, TumorMiceNanoparticles

Keywords

SuppressorImmunityNanoengineeringImmunotherapyCancerMyeloid-derived Suppressor CellImmunologyPancreatic cancerCancer researchImmune systemMedicineBiologyInternal medicineTargetingHomingNanoparticleAntitumor immunityimmunosuppressionMyeloid-derived Suppressor CellsCxcr2Neutrophil’Receptors, Interleukin-8BMiceCell Line, TumorNitrilesImmune ToleranceAnimalsHumansRC254-282Brief ReportNeoplasms. Tumors. Oncology. Including cancer and carcinogensPancreatic NeoplasmsMice, Inbred C57BLPyrimidinesPyrazolesNanoparticlesFemaleCarcinoma, Pancreatic DuctalSignal Transduction

Sustainable Development Goals

SDG 0: Good health and well-being

Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer

FAIR Checklist

Authors (13)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)